{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:13:58Z","timestamp":1789812838265,"version":"4.0.1"},"reference-count":171,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart failure (HF) affects more than 60 million people worldwide, with significant discrepancies in diagnosis and management. Moreover, HF is associated with elevated mortality and hospitalization rates, increasing in the last decades. The universal definition of HF included a staging system (Stages A\u2013D) specifically focused on disease progression. Patients \u2018at risk\u2019 for HF (but without current or prior symptoms or signs of HF and without structural cardiac changes or elevated biomarkers of heart disease) represent Stage A. The \u2018pre-heart failure\u2019 refers to Stage B, in which the patients display at least one of the following conditions: the evidence of structural heart disease, impaired cardiac function, or elevated cardiac biomarkers -such as troponins or natriuretic peptides (NPs). The specific purpose of this classification is to improve the early detection, risk stratification, and prevention of disease progression, promoting specific actions focused on the early risk identification and the optimization of metabolic and cardiovascular factors that could potentially favour the HF onset and progression. In this review, an expert panel analysed both the risk and the promoting factors for HF progression to early identify patients with higher risk of progression. In addition, a score has been proposed, based on a comprehensive evaluation of the patients through the identification of the HF risk factors, the NP levels, and the echocardiographic measurement, to help clinicians in early HF diagnosis. Overall, the lifestyle modifications and the intensive treatment of HF risk factors using old (ACEis\/ARBs) and new drugs (SGLT2is, GLP1 RAs, and nsMRAs) could prevent HF progression from Stage A to Stage B improving HF prognosis.<\/jats:p>","DOI":"10.1093\/eurjpc\/zwag484","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:24:31Z","timestamp":1788780271000},"source":"Crossref","is-referenced-by-count":0,"title":["The transition from stage A to stage B of heart failure: risk factors, promoting factors, and opportunities for prevention: an update from the Italian Society of Cardiology Working Group on Heart Failure"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-1429","authenticated-orcid":false,"given":"Gaetano","family":"Ruocco","sequence":"first","affiliation":[{"name":"Cardiology Unit, \u2018I Veris delli Ponti\u2019 Hospital, ASL Lecce , Via Giuseppina delli Ponti, Scorrano 73020 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Correale","sequence":"additional","affiliation":[{"name":"Emergency and Urgency Department, Ospedali Riuniti University Hospital , Foggia 71100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Beltrami","sequence":"additional","affiliation":[{"name":"Arrhythmia and Electrophysiology Unit, Careggi University Hospital , Largo Brambilla 3, Florence 50135 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Salzano","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, Federico II\u2019 University , Naples ,","place":["Italy"]},{"name":"Interdepartmental Center for Gender Medicine Research \u2018GENESIS\u2019 , Federico II University, Naples ,","place":["Italy"]},{"name":"AORN A Cardarelli Cardiology Unit, , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Severino","sequence":"additional","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, Sapienza University of Rome , Rome 00161 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Naples Federico II , Via Sergio Pansini 5, Naples 80131 ,","place":["Italy"]},{"name":"Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Mercurio","sequence":"additional","affiliation":[{"name":"Department of Translational Medical Sciences, University of Naples Federico II , Via Sergio Pansini 5, Naples 80131 ,","place":["Italy"]},{"name":"Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Tricarico","sequence":"additional","affiliation":[{"name":"Emergency and Urgency Department, Ospedali Riuniti University Hospital , Foggia 71100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4683-0993","authenticated-orcid":false,"given":"Stefania","family":"Paolillo","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8845-7010","authenticated-orcid":false,"given":"Giulia","family":"Crisci","sequence":"additional","affiliation":[{"name":"Division of Cardiology, San Paolo University Hospital, University of Milano School of Medicine , Milan ,","place":["Italy"]},{"name":"Department of Cardiology, Jessa and Science, Jessa Hospital , Hasselt ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Barill\u00e0","sequence":"additional","affiliation":[{"name":"UniCamillus-Saint Camillus International University of Health Sciences , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Dattilo","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Dental Sciences, and Morphofunctional Imaging, Cardiology Unit, University of Messina , Messina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Micari","sequence":"additional","affiliation":[{"name":"Department of Biomedical, Dental Sciences, and Morphofunctional Imaging, Cardiology Unit, University of Messina , Messina ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank Lloyd","family":"Dini","sequence":"additional","affiliation":[{"name":"Istituto Auxologico Italiano I.R.C.C.S. Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erberto","family":"Carluccio","sequence":"additional","affiliation":[{"name":"Cardiology and Cardiovascular Pathophysiology Unit, Santa Maria della Misericordia Hospital, University of Perugia , Perugia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savina","family":"Nodari","sequence":"additional","affiliation":[{"name":"Section of Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia , Brescia ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1674-5317","authenticated-orcid":false,"given":"Angela","family":"Sciacqua","sequence":"additional","affiliation":[{"name":"Geriatrics Division, \u2018Renato Dulbecco\u2019 University Hospital of Catanzaro , Catanzaro ,","place":["Italy"]},{"name":"Department of Medical and Surgical Sciences, University Magna Gr\u00e6cia of Catanzaro , Catanzaro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-4983","authenticated-orcid":false,"given":"Carmine Dario","family":"Vizza","sequence":"additional","affiliation":[{"name":"Department of Medical and Cardiovascular Sciences, Sapienza University of Rome , Rome 00161 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Perrone Filardi","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, Federico II University of Naples , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Sinagra","sequence":"additional","affiliation":[{"name":"Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste , Via P. Valdoni 7, Trieste 34100 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-984X","authenticated-orcid":false,"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[{"name":"Cardiovascular Diseases Unit, Cardio-Thoracic and Vascular Department, Le Scotte Hospital, University of Siena , Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"2026091905420508200_zwag484-B1","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/eurjpc\/zwaa147","article-title":"Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017","volume":"28","author":"Bragazzi","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026091905420508200_zwag484-B2","first-page":"e41","article-title":"2025 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B3","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/ejhf.3707","article-title":"Global heart failure epidemiology versus enrolment in pivotal trials: a formidable mismatch","volume":"27","author":"Baudry","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026091905420508200_zwag484-B4","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1001\/jama.2023.5942","article-title":"Global variations in heart failure etiology, management, and outcomes","volume":"329","author":"G-CHF Investigators","year":"2023","journal-title":"JAMA"},{"key":"2026091905420508200_zwag484-B5","first-page":"06703-3","article-title":"AHA\/ACC\/ESC\/WHF expert consensus document: second universal definition of heart failure (2026)","volume":"S0735-1097","author":"Walsh","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B6","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1093\/eurheartj\/ehaf431","article-title":"Clinical staging to guide management of metabolic disorders and their sequelae: a European atherosclerosis society consensus statement","volume":"46","author":"Romeo","year":"2025","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B7","first-page":"S13","article-title":"New strategies and therapies for the prevention of heart failure in high-risk patients","volume":"45 Suppl 1","author":"Hammond","year":"2022","journal-title":"Clin Cardiol"},{"key":"2026091905420508200_zwag484-B8","doi-asserted-by":"crossref","first-page":"e1006","DOI":"10.1161\/CIR.0000000000001307","article-title":"Risk-based primary prevention of heart failure: a scientific statement from the American Heart Association","volume":"151","author":"Khan","year":"2025","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B9","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jchf.2013.11.007","article-title":"Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis","volume":"2","author":"Savarese","year":"2014","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B10","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1002\/ehf2.13576","article-title":"NT-proBNP\/BNP ratio for prognostication in European Caucasian patients enrolled in a heart failure prevention programme","volume":"8","author":"Sweeney","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026091905420508200_zwag484-B11","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1161\/CIR.0000000000001191","article-title":"Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association","volume":"148","author":"Khan","year":"2023","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B12","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf213","article-title":"External validation of the 2023 American Heart Association predicting risk of cardiovascular disease EVENTs equations for atherosclerotic cardiovascular disease in primary cardiovascular prevention setting and comparison with 2021 systematic COronary risk evaluation and 2013 pooled cohort equations","author":"Roxane","journal-title":"Eur J Prev Cardiol"},{"key":"2026091905420508200_zwag484-B13","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0897190016639196","article-title":"Retrospective evaluation of ASCVD risk and statin therapy need in nondiabetic patients based on the 2013 ACC\/AHA cholesterol guidelines","volume":"30","author":"Koenigsfeld","year":"2017","journal-title":"J Pharm Pract"},{"key":"2026091905420508200_zwag484-B14","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"2026091905420508200_zwag484-B15","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.125.043944","article-title":"Preclinical heart failure: a dynamic trajectory of progression, regression, and risk","volume":"15","author":"Moore","year":"2026","journal-title":"J Am Heart Assoc"},{"key":"2026091905420508200_zwag484-B16","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nrcardio.2016.25","article-title":"Epidemiology and aetiology of heart failure","volume":"13","author":"Ziaeian","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"2026091905420508200_zwag484-B17","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the framingham heart study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B18","article-title":"Hypertension and heart failure: from pathophysiology to treatment","volume":"25","author":"Gallo","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"16","key":"2026091905420508200_zwag484-B19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/hrt.2011.225482","article-title":"Systolic blood pressure and incident heart failure in the elderly. The Cardiovascular Health Study and the Health, Ageing and Body Composition Study","volume":"97","author":"Butler","year":"2011","journal-title":"Heart"},{"issue":"25","key":"2026091905420508200_zwag484-B20","first-page":"2506","article-title":"A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373(22):2103\u20132116. Erratum","volume":"377","author":"SPRINT Research Group","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091905420508200_zwag484-B21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005253","article-title":"Progression of coronary artery calcium and incident heart failure: the multi-ethnic study of atherosclerosis","volume":"6","author":"Bakhshi","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026091905420508200_zwag484-B22","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12968-018-0428-0","article-title":"Systemic arteriosclerosis is associated with left ventricular remodeling but not atherosclerosis: a TASCFORCE study","volume":"20","author":"Weir-McCall","year":"2018","journal-title":"J Cardiovasc Magn Reson"},{"issue":"2","key":"2026091905420508200_zwag484-B23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S2213-8587(14)70219-0","article-title":"Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people","volume":"3","author":"Shah","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2026091905420508200_zwag484-B24","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jchf.2021.06.005","article-title":"Duration of diabetes and incident heart failure: The ARIC (Atherosclerosis Risk In Communities) study","volume":"9","author":"Echouffo-Tcheugui","year":"2021","journal-title":"JACC Heart Fail"},{"issue":"5","key":"2026091905420508200_zwag484-B25","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jacc.2021.05.004","article-title":"Cardiovascular and kidney outcomes across the glycemic spectrum: insights from the UK Biobank","volume":"78","author":"Honigberg","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B26","first-page":"e876","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/echo.14580","article-title":"Association between left ventricular diastolic dysfunction and subclinical coronary artery calcification","volume":"37","author":"Mansour","year":"2020","journal-title":"Echocardiography"},{"key":"2026091905420508200_zwag484-B28","article-title":"Extent of coronary atherosclerosis is associated with deterioration of left ventricular global longitudinal strain in patients with preserved ejection fraction undergoing coronary computed tomography angiography","volume":"44","author":"Ishikawa","year":"2023","journal-title":"Int J Cardiol Heart Vasc"},{"key":"2026091905420508200_zwag484-B29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B30","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2025.106457","article-title":"Non cardiovascular comorbidities in heart failure. An updated position paper from the heart failure working group of the Italian society of cardiology (SIC)","volume":"140","author":"Correale","year":"2025","journal-title":"Eur J Intern Med"},{"key":"2026091905420508200_zwag484-B31","doi-asserted-by":"publisher","first-page":"e294","DOI":"10.1161\/CIR.0000000000000735","article-title":"Type 2 diabetes Mellitus and heart failure: a scientific statement from the American Heart Association and the heart failure society of America: this statement does not represent an update of the 2017 ACC\/AHA\/HFSA heart failure guideline update","volume":"140","author":"Dunlay","year":"2019","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B32","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.numecd.2018.07.005","article-title":"Diabetes mellitus, blood glucose and the risk of heart failure: a systematic review and meta-analysis of prospective studies","volume":"28","author":"Aune","year":"2018","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2026091905420508200_zwag484-B33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23073587","article-title":"Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes mellitus","volume":"23","author":"Nakamura","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2026091905420508200_zwag484-B34","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.amjcard.2003.12.026","article-title":"Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus","volume":"93","author":"Boyer","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026091905420508200_zwag484-B35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pcad.2024.01.003","article-title":"Update on obesity, the obesity paradox, and obesity management in heart failure","volume":"82","author":"Alebna","year":"2024","journal-title":"Prog Cardiovasc Dis"},{"key":"2026091905420508200_zwag484-B36","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(25)00006-3","article-title":"Definition and diagnostic criteria of clinical obesity","volume":"13","author":"Rubino","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091905420508200_zwag484-B37","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehac458","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B38","first-page":"30","article-title":"Endothelial dysfunction and heart failure with preserved ejection fraction-an updated review of the literature","volume":"14","author":"De Luca","year":"2023","journal-title":"Life (Basel)"},{"key":"2026091905420508200_zwag484-B39","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","article-title":"Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association","volume":"119","author":"Zoccali","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026091905420508200_zwag484-B40","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1177\/2047487312462826","article-title":"Of heart and kidney: a complicated love story","volume":"21","author":"Gaita","year":"2014","journal-title":"Eur J Prev Cardiol"},{"key":"2026091905420508200_zwag484-B41","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001241","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B42","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1016\/j.jacc.2026.03.056","article-title":"2026 AHA\/ACC\/ADA\/ASN guideline for the prevention, detection, evaluation, and management of cardiovascular-kidney-metabolic syndrome: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"87","author":"Ndumele","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-026-01078-w","article-title":"Epidemiology of cardiovascular-kidney-metabolic syndrome","author":"Mavromatis","journal-title":"Nat Rev Nephrol"},{"key":"2026091905420508200_zwag484-B44","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s12933-026-03177-1","article-title":"Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management","volume":"25","author":"Jankauskas","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"2026091905420508200_zwag484-B45","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/eurheartj\/ehae288","article-title":"Incident heart failure in chronic kidney disease: proteomics informs biology and risk stratification","volume":"45","author":"Dubin","year":"2024","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B46","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B47","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/ejhf.2469","article-title":"Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial","volume":"24","author":"Filippatos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026091905420508200_zwag484-B48","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jchf.2022.03.004","article-title":"Increase in BNP in response to endothelin-receptor antagonist atrasentan is associated with incident heart failure","volume":"10","author":"Smeijer","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.15420\/cfr.2018.32.2","article-title":"Heart failure and cancer: mechanisms of old and new cardiotoxic drugs in cancer patients","volume":"5","author":"Cuomo","year":"2019","journal-title":"Card Fail Rev"},{"key":"2026091905420508200_zwag484-B50","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.cardfail.2016.04.008","article-title":"Models of heart failure based on the cardiotoxicity of anticancer drugs","volume":"22","author":"Mercurio","year":"2016","journal-title":"J Card Fail"},{"key":"2026091905420508200_zwag484-B51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphys.2018.00167","article-title":"Antineoplastic drug-induced cardiotoxicity: a redox perspective","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front Physiol"},{"key":"2026091905420508200_zwag484-B52","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026091905420508200_zwag484-B53","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jchf.2018.08.005","article-title":"Frequency of transition from stage a to stage b heart failure after initiating potentially cardiotoxic chemotherapy","volume":"6","author":"Jones","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B54","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehad196","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B55","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B56","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000054","article-title":"Establishment of specialized clinical cardiovascular genetics programs: recognizing the need and meeting standards: a scientific statement from the American Heart Association","volume":"12","author":"Ahmad","year":"2019","journal-title":"Circ Genom Precis Med"},{"key":"2026091905420508200_zwag484-B57","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jacc.2021.08.039","article-title":"Association of genetic variants with outcomes in patients with nonischemic dilated cardiomyopathy","volume":"78","author":"Escobar-Lopez","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B58","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41569-024-01074-2","article-title":"Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine","volume":"22","author":"Gigli","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"2026091905420508200_zwag484-B59","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","article-title":"Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe)","volume":"138","author":"Ho","year":"2018","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B60","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1161\/CIRCGEN.122.003832","article-title":"Long-term prevalence of systolic dysfunction in MYBPC3 versus MYH7-related hypertrophic cardiomyopathy","volume":"16","author":"Beltrami","year":"2023","journal-title":"Circ Genom Precis Med"},{"key":"2026091905420508200_zwag484-B61","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.jacc.2005.05.087","article-title":"Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac Myosin-binding protein C gene among Japanese","volume":"46","author":"Kubo","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B62","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1016\/j.jacc.2014.09.059","article-title":"Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations","volume":"64","author":"Coppini","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/ehjqcco\/qcac006","article-title":"Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy\/Myocarditis registry","volume":"9","author":"Lopes","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026091905420508200_zwag484-B64","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.120.007216","article-title":"Progression of preclinical heart failure: a description of stage A and B heart failure in a community population","volume":"14","author":"Young","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026091905420508200_zwag484-B65","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1177\/2047487320922636","article-title":"Prevalence and determinants of the precursor stages of heart failure: results from the population-based STAAB cohort study","volume":"28","author":"Morbach","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026091905420508200_zwag484-B66","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jchf.2024.09.022","article-title":"Clinical and proteomic risk profiles of new-onset heart failure in men and women","volume":"13","author":"Qin","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B67","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2010.165","article-title":"Epidemiology and risk profile of heart failure","volume":"8","author":"Bui","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"2026091905420508200_zwag484-B68","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/j.jacc.2025.05.008","article-title":"2025 ACC scientific statement on the management of obesity in adults with heart failure: a report of the American College of Cardiology","volume":"86","author":"Kittleson","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B69","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae915","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B70","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","article-title":"Epicardial adipose tissue in contemporary cardiology","volume":"19","author":"Iacobellis","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"2026091905420508200_zwag484-B71","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0735-1097(01)01195-0","article-title":"Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction","volume":"37","author":"Suskin","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B72","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1001\/archinte.1994.00420040081012","article-title":"Modifiable risk factors for incident heart failure in the coronary artery surgery study","volume":"154","author":"Hoffman","year":"1994","journal-title":"Arch Intern Med"},{"key":"2026091905420508200_zwag484-B73","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.jchf.2017.10.007","article-title":"The transition from hypertension to heart failure: contemporary update","volume":"5","author":"Messerli","year":"2017","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B74","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011724","article-title":"Unraveling comorbidities contribution to cardiac diastolic dysfunction and heart failure","volume":"18","author":"Villalba-Orero","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026091905420508200_zwag484-B75","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/eurjpc\/zwad344","article-title":"Blood pressure, hypertension, and the risk of heart failure: a systematic review and meta-analysis of cohort studies","volume":"31","author":"Baffour","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"2026091905420508200_zwag484-B76","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1161\/CIRCRESAHA.124.325488","article-title":"Renal-cardiac crosstalk in the pathogenesis and progression of heart failure","volume":"136","author":"Noels","year":"2025","journal-title":"Circ Res"},{"key":"2026091905420508200_zwag484-B77","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10741-022-10238-6","article-title":"Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence","volume":"28","author":"Palazzuoli","year":"2023","journal-title":"Heart Fail Rev"},{"key":"2026091905420508200_zwag484-B78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2025.133554","article-title":"Diabetic cardiomyopathy revisited: the interplay between diabetes and heart failure","volume":"438","author":"Mann","year":"2025","journal-title":"Int J Cardiol"},{"key":"2026091905420508200_zwag484-B79","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12933-022-01543-3","article-title":"Progressive right ventricular dysfunction and exercise impairment in patients with heart failure and diabetes mellitus: insights from the T.O.S.CA. Registry","volume":"21","author":"Salzano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2026091905420508200_zwag484-B80","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1161\/HYPERTENSIONAHA.123.21304","article-title":"Nocturnal hypertension and left ventricular diastolic dysfunction in patients with diabetes with the absence of heart failure: prospective cohort HSCAA study","volume":"81","author":"Kidawara","year":"2024","journal-title":"Hypertension"},{"key":"2026091905420508200_zwag484-B81","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091905420508200_zwag484-B82","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.103.16.2055","article-title":"Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the vesnarinone trial (VEST)","volume":"103","author":"Deswal","year":"2001","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B83","first-page":"287","article-title":"Role of interleukins in heart failure with reduced ejection fraction","volume":"22","author":"Segiet","year":"2019","journal-title":"Anatol J Cardiol"},{"key":"2026091905420508200_zwag484-B84","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1067\/mhj.2001.112785","article-title":"Effect of metoprolol on cytokine levels in chronic heart failure\u2013a substudy in the metoprolol controlled-release randomised intervention trial in heart failure (MERIT-HF)","volume":"141","author":"Gullestad","year":"2001","journal-title":"Am Heart J"},{"key":"2026091905420508200_zwag484-B85"},{"key":"2026091905420508200_zwag484-B86","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41593-023-01377-6","article-title":"Heart failure-induced cognitive dysfunction is mediated by intracellular Ca2+ leak through ryanodine receptor type 2","volume":"26","author":"Dridi","year":"2023","journal-title":"Nat Neurosci"},{"key":"2026091905420508200_zwag484-B87","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20163986","article-title":"Calcium as a key player in arrhythmogenic cardiomyopathy: adhesion disorder or intracellular alteration?","volume":"20","author":"Moccia","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026091905420508200_zwag484-B88","doi-asserted-by":"crossref","first-page":"H2181","DOI":"10.1152\/ajpheart.00554.2011","article-title":"Oxidative stress and heart failure","volume":"301","author":"Tsutsui","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026091905420508200_zwag484-B89","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s40520-025-03049-w","article-title":"Gliflozines as add-on to Arni in echocardiographic, sarcopenic and oxidative stress parameters in elderly patients with chronic heart failure","volume":"37","author":"Armentaro","year":"2025","journal-title":"Aging Clin Exp Res"},{"key":"2026091905420508200_zwag484-B90","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25168811","article-title":"Effects of SGLT2-inhibitors on comprehensive geriatric assessment, biomarkers of oxidative stress, and platelet activation in elderly diabetic patients with heart failure with preserved ejection fraction","volume":"25","author":"Magurno","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026091905420508200_zwag484-B91","article-title":"Oxidative stress parameters as biomarkers of cardiovascular disease towards the development and progression","volume":"11","author":"Kong","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"2026091905420508200_zwag484-B92","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110241","article-title":"Damage-associated molecular patterns (DAMPs) in vascular diseases","volume":"301","author":"Antonello","year":"2025","journal-title":"J Biol Chem"},{"key":"2026091905420508200_zwag484-B93","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1093\/eurheartj\/ehz961","article-title":"Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease","volume":"41","author":"Liberale","year":"2020","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B94","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1161\/CIRCRESAHA.121.318159","article-title":"From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited","volume":"128","author":"Paulus","year":"2021","journal-title":"Circ Res"},{"key":"2026091905420508200_zwag484-B95","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure: JACC state-of-the-art review","volume":"75","author":"Murphy","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B96","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00011-013-0625-0","article-title":"Interleukin-1\u03b2 induces a reversible cardiomyopathy in the mouse","volume":"62","author":"Van Tassell","year":"2013","journal-title":"Inflamm Res"},{"key":"2026091905420508200_zwag484-B97","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","article-title":"Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week","volume":"74","author":"Aimo","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B98","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B99","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13467","article-title":"Late-in-life treadmill training rejuvenates autophagy, protein aggregate clearance, and function in mouse hearts","volume":"20","author":"Cho","year":"2021","journal-title":"Aging Cell"},{"key":"2026091905420508200_zwag484-B100","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jacc.2010.10.024","article-title":"Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction","volume":"57","author":"Kasner","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B101","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.recesp.2016.12.018","article-title":"Role of myocardial collagen in severe aortic stenosis with preserved ejection fraction and symptoms of heart failure","volume":"70","author":"Echegaray","year":"2017","journal-title":"Rev Esp Cardiol (Engl ed)"},{"key":"2026091905420508200_zwag484-B102","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.006939","article-title":"Elevated angiotensin 1-7\/angiotensin ii ratio predicts favorable outcomes in patients with heart failure","volume":"13","author":"Wang","year":"2020","journal-title":"Circ Heart Fail"},{"key":"2026091905420508200_zwag484-B103","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/01.HYP.0000254415.31362.a7","article-title":"Role of oxidative stress in cardiac hypertrophy and remodeling","volume":"49","author":"Takimoto","year":"2007","journal-title":"Hypertens"},{"key":"2026091905420508200_zwag484-B104","first-page":"717","article-title":"Subclinical inflammation in heart failure: a neutrophil perspective","volume":"34","author":"Vulesevic","year":"2018","journal-title":"Can J Cardiol"},{"key":"2026091905420508200_zwag484-B105","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1002\/ehf2.14362","article-title":"Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction","volume":"8","author":"Curran","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026091905420508200_zwag484-B106","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","article-title":"Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction","volume":"110","author":"Sharma","year":"2004","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/1440-1681.13048","article-title":"The role of galectin-3 in heart failure and cardiovascular disease","volume":"46","author":"Zhong","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2026091905420508200_zwag484-B108","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0140-6736(11)60894-5","article-title":"In search of new therapeutic targets and strategies for heart failure: recent advances in basic science","volume":"378","author":"Shah","year":"2011","journal-title":"Lancet"},{"key":"2026091905420508200_zwag484-B109","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000503058","article-title":"Hyperuricemia in US population with heart failure: causal or incidental bystander?","volume":"9","author":"Ruocco","year":"2019","journal-title":"Cardiorenal Med"},{"key":"2026091905420508200_zwag484-B110","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1002\/ehf2.13375","article-title":"Proteomic profiling for detection of early-stage heart failure in the community","volume":"8","author":"Cauwenberghs","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026091905420508200_zwag484-B111","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12041612","article-title":"Exploring the cardiotoxicity spectrum of anti-cancer treatments: definition, classification, and diagnostic pathways","volume":"12","author":"Mauro","year":"2023","journal-title":"J Clin Med"},{"key":"2026091905420508200_zwag484-B112","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12062121","article-title":"Cardiovascular side effects of anthracyclines and HER2 inhibitors among patients with breast cancer: a multidisciplinary stepwise approach for prevention, early detection, and treatment","volume":"12","author":"Mauro","year":"2023","journal-title":"J Clin Med"},{"key":"2026091905420508200_zwag484-B113","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12237214","article-title":"Biomarkers in acute myocarditis and chronic inflammatory cardiomyopathy: an updated review of the literature","volume":"12","author":"Crisci","year":"2023","journal-title":"J Clin Med"},{"key":"2026091905420508200_zwag484-B114","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jew041","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026091905420508200_zwag484-B115","first-page":"72","article-title":"L'insufficienza cardiaca nella cardiopatia ipertensiva [cardiac failure in hypertensive cardiopathy]","volume":"1 Suppl 2","author":"Verdecchia","year":"2000","journal-title":"Ital Heart J"},{"key":"2026091905420508200_zwag484-B116","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ehjci\/jew082","article-title":"Recommendations for the evaluation of left ventricular diastolic function by echocardiography: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"17","author":"Nagueh","year":"2016","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026091905420508200_zwag484-B117","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.jacc.2017.01.058","article-title":"Estimating left ventricular filling pressure by echocardiography","volume":"69","author":"Andersen","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B118","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014605","article-title":"Left atrial strain in the assessment of diastolic function in heart failure: a machine learning approach","volume":"16","author":"Carluccio","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026091905420508200_zwag484-B119","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1093\/ehjci\/jeab154","article-title":"Multimodality imaging in patients with heart failure and preserved ejection fraction: an expert consensus document of the European Association of Cardiovascular Imaging","volume":"23","author":"Smiseth","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026091905420508200_zwag484-B120","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/clc.20617","article-title":"Plasma N-terminal protype-B natriuretic peptide and restrictive mitral flow to risk-stratify patients with stage B heart failure","volume":"32","author":"Dini","year":"2009","journal-title":"Clin Cardiol"},{"key":"2026091905420508200_zwag484-B121","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ejhf.694","article-title":"Myocardial strain to detect subtle left ventricular systolic dysfunction","volume":"19","author":"Tops","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026091905420508200_zwag484-B122","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.echo.2021.09.003","article-title":"Incremental value of global longitudinal strain in the long-term prediction of heart failure among patients with coronary artery disease","volume":"35","author":"Haji","year":"2022","journal-title":"J Am Soc Echocardiogr"},{"key":"2026091905420508200_zwag484-B123","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","article-title":"Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American society of echocardiography developed in collaboration with the society for cardiovascular magnetic resonance","volume":"30","author":"Zoghbi","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"2026091905420508200_zwag484-B124","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.echo.2022.03.012","article-title":"Recommendations for multimodality cardiovascular imaging of patients with hypertrophic cardiomyopathy: an update from the American society of echocardiography, in collaboration with the American society of nuclear cardiology, the society for cardiovascular magnetic resonance, and the society of cardiovascular computed tomography","volume":"35","author":"Nagueh","year":"2022","journal-title":"J Am Soc Echocardiogr"},{"key":"2026091905420508200_zwag484-B125","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.echo.2025.05.001","article-title":"Guidelines for the echocardiographic assessment of the right heart in adults and special considerations in pulmonary hypertension: recommendations from the American society of echocardiography","volume":"38","author":"Mukherjee","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"key":"2026091905420508200_zwag484-B126","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.117.006894","article-title":"Prognostic value of right ventricular dysfunction in heart failure with reduced ejection fraction: superiority of longitudinal strain over tricuspid annular plane systolic excursion","volume":"11","author":"Carluccio","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026091905420508200_zwag484-B127","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/ehjci\/jeu313","article-title":"Accuracy of cardiac CT, radionucleotide and invasive ventriculography, two- and three-dimensional echocardiography, and SPECT for left and right ventricular ejection fraction compared with cardiac MRI: a meta-analysis","volume":"16","author":"Pickett","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026091905420508200_zwag484-B128","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/eurheartj\/ehs016","article-title":"A novel clinical method for quantification of regional left ventricular pressure-strain loop area: a non-invasive index of myocardial work","volume":"33","author":"Russell","year":"2012","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B129","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1093\/eurheartj\/ehag362","article-title":"Prevention of heart failure","volume":"47","author":"Piepoli","year":"2026","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B130","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1016\/j.jacc.2022.03.377","article-title":"Cigarette smoking, cessation, and risk of heart failure with preserved and reduced ejection fraction","volume":"79","author":"Ding","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B131","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2022.04.006","article-title":"Is smoking cessation the best intervention ever to prevent heart failure?","volume":"79","author":"Biondi-Zoccai","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B132","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jchf.2022.07.006","article-title":"Smoking cessation reduces the risk of heart failure: a nationwide cohort study","volume":"11","author":"Yoo","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B133","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosis.2015.08.039","article-title":"A Mediterranean diet and risk of myocardial infarction, heart failure and stroke: a population-based cohort study","volume":"243","author":"Tektonidis","year":"2015","journal-title":"Atherosclerosis"},{"key":"2026091905420508200_zwag484-B134","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/ejcn.2016.140","article-title":"A Mediterranean-style diet, its components and the risk of heart failure: a prospective population-based study in a non-Mediterranean country","volume":"70","author":"Wirth","year":"2016","journal-title":"Eur J Clin Nutr"},{"key":"2026091905420508200_zwag484-B135","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1161\/CIRCULATIONAHA.115.015853","article-title":"Dose-response relationship between physical activity and risk of heart failure: a meta-analysis","volume":"132","author":"Pandey","year":"2015","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B136","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ahj.2014.11.006","article-title":"Critical impact of fitness in the prevention and treatment of heart failure","volume":"169","author":"Lavie","year":"2015","journal-title":"Am Heart J"},{"key":"2026091905420508200_zwag484-B137","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jchf.2015.05.006","article-title":"Physical activity and heart failure risk in a prospective study of men","volume":"3","author":"Rahman","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B138","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.115.002855","article-title":"Healthy lifestyle and risk of heart failure: results from 2 prospective cohort studies","volume":"9","author":"Larsson","year":"2016","journal-title":"Circ Heart Fail"},{"key":"2026091905420508200_zwag484-B139","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.mayocp.2024.08.007","article-title":"Association of plasma omega-3 levels with incident heart failure and related mortalities","volume":"99","author":"Jawad","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"2026091905420508200_zwag484-B140","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jchf.2019.03.008","article-title":"Predicting risk for incident heart failure with omega-3 fatty acids: from MESA","volume":"7","author":"Block","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B141","doi-asserted-by":"crossref","first-page":"e867","DOI":"10.1161\/CIR.0000000000000482","article-title":"Omega-3 polyunsaturated fatty acid (Fish Oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association","volume":"135","author":"Siscovick","year":"2017","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B142","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jchf.2021.12.006","article-title":"Diabetes Mellitus, race, and effects of Omega-3 fatty acids on incidence of heart failure hospitalization","volume":"10","author":"Djouss\u00e9","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B143","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.jacc.2011.06.063","article-title":"Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events","volume":"58","author":"Mozaffarian","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B144","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.mayocp.2024.10.011","article-title":"Omega-3 fish oils in prevention and management of heart failure","volume":"99","author":"Lavie","year":"2024","journal-title":"Mayo Clin Proc"},{"key":"2026091905420508200_zwag484-B145","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jacc.2023.05.024","article-title":"Omega-3 fatty acid biomarkers and incident atrial fibrillation","volume":"82","author":"Qian","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026091905420508200_zwag484-B146","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.121.055654","article-title":"Effect of long-term marine \u0277-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis","volume":"144","author":"Gencer","year":"2021","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B147","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1517\/14656566.2012.683175","article-title":"Effects of valsartan or ramipril addition to amlodipine\/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy","volume":"13","author":"Fogari","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"2026091905420508200_zwag484-B148","article-title":"First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension","volume":"1","author":"Xue","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026091905420508200_zwag484-B149","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.clinthera.2005.05.006","article-title":"Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study","volume":"27","author":"Ruilope","year":"2005","journal-title":"Clin Ther"},{"key":"2026091905420508200_zwag484-B150","first-page":"1359","article-title":"Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial","volume":"15","author":"Ca\u011flar","year":"2011","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026091905420508200_zwag484-B151","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjhyper.2007.03.009","article-title":"Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy","volume":"20","author":"Seeman","year":"2007","journal-title":"Am J Hypertens"},{"key":"2026091905420508200_zwag484-B152","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/j.jchf.2024.08.007","article-title":"Mineralocorticoid antagonism in heart failure: established and emerging therapeutic role","volume":"12","author":"Chang","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B153","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.124.011629","article-title":"Mineralocorticoid receptor antagonists in heart failure: an update","volume":"17","author":"Ferreira","year":"2024","journal-title":"Circ Heart Fail"},{"key":"2026091905420508200_zwag484-B154","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2025.101762","article-title":"Aldosterone-related cardiovascular disease and benefits of mineralocorticoid receptor antagonists in clinical practice","volume":"4","author":"Alfarano","year":"2025","journal-title":"JACC Adv"},{"key":"2026091905420508200_zwag484-B155","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"2026091905420508200_zwag484-B156","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab670","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B157","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad613","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026091905420508200_zwag484-B158","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026091905420508200_zwag484-B159","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","article-title":"Empagliflozin reduced mortality and hospitalization for heart failure across the Spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial","volume":"139","author":"Fitchett","year":"2019","journal-title":"Circulation"},{"key":"2026091905420508200_zwag484-B160","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026091905420508200_zwag484-B161","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.2073","article-title":"Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58","volume":"23","author":"Zelniker","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026091905420508200_zwag484-B162","doi-asserted-by":"crossref","first-page":"41","DOI":"10.31083\/j.rcm.2018.02.907","article-title":"Cardiorenal outcomes in the CANVAS, DECLARE-TIMI 58, and EMPA-REG OUTCOME trials: a systematic review","volume":"19","author":"Kluger","year":"2018","journal-title":"Rev Cardiovasc Med"},{"key":"2026091905420508200_zwag484-B163","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10741-021-10157-y","article-title":"Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients","volume":"28","author":"Correale","year":"2023","journal-title":"Heart Fail Rev"},{"key":"2026091905420508200_zwag484-B164","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091905420508200_zwag484-B165","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12933-018-0800-2","article-title":"GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data","volume":"17","author":"Sposito","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2026091905420508200_zwag484-B166","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/dom.14997","article-title":"Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials","volume":"25","author":"Ferreira","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2026091905420508200_zwag484-B167","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/s10557-023-07432-5","article-title":"Impact of heart failure history at baseline on cardiovascular effects of GLP-1 receptor agonists in type 2 diabetes: a meta-analysis","volume":"38","author":"Banerjee","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026091905420508200_zwag484-B168","article-title":"GLP-1 receptor agonists for the prevention of new-onset heart failure: a systematic review and meta-analysis of placebo-controlled randomized clinical trials","volume":"27","author":"Neves","year":"2025","journal-title":"Obes Rev"},{"key":"2026091905420508200_zwag484-B169","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jchf.2023.05.010","article-title":"Design and baseline characteristics of step-hfpef program evaluating semaglutide in patients with obesity HFpEF phenotype","volume":"11","author":"Kosiborod","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026091905420508200_zwag484-B170","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"2026091905420508200_zwag484-B171","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/ejhf.3036","article-title":"Practical algorithms for early diagnosis of heart failure and heart stress using NT-proBNP: a clinical consensus statement from the heart failure association of the ESC","volume":"25","author":"Bayes-Genis","year":"2023","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag484\/71010950\/zwag484.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwag484\/71010950\/zwag484.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:42:31Z","timestamp":1789810951000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article\/doi\/10.1093\/eurjpc\/zwag484\/8789476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":171,"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwag484","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"article-number":"zwag484"}}